| Symbol | IMTX |
|---|---|
| Name | IMMATICS N.V. |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | PAUL-EHRLICH-STRAÿE 15, TUBINGEN, 72076, Germany |
| Telephone | +49 707153970 |
| Fax | — |
| — | |
| Website | https://www.immatics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001809196 |
| Description | Immatics NV is engaged in the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The companys pipeline consists of two lead product classes, engineered Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics (TCER). Each therapeutic modality has distinct attributes to produce the desired therapeutic effect for patients at different disease stages and with different types of tumors focusing on particularly hard-to-treat solid cancers. Additional info from NASDAQ: |
Pepin James Nelson 🟢 acquired 225.0K shares (2 derivative) of Immatics N.V. (IMTX) at $9.44 ($1.7M) Transaction Date: Aug 14, 2026 | Filing ID: 012582
Read moreImmatics Announces Second Quarter 2026 Financial Results and Business Update
Read moreNew Form 3 - Immatics N.V. <b>Filed:</b> 2026-07-29 <b>AccNo:</b> 0000950103-26-011324 <b>Size:</b> 13 KB
Read moreImmatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026
Read moreNew Form S-8 - Immatics N.V. <b>Filed:</b> 2026-06-25 <b>AccNo:</b> 0000950103-26-009506 <b>Size:</b> 247 KB
Read moreDirector Stone Adam Leo 🟢 acquired 48.0K shares (1 derivative) of Immatics N.V. (IMTX) at $9.09 Transaction Date: Jun 16, 2026 | Filing ID: 009251
Read moreImmatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
Read moreImmatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
Read moreImmatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting
Read moreNew Form SCHEDULE 13G/A - Immatics N.V. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0000902664-26-002549 <b>Size:</b> 10 KB
Read more